Dec 2018 APPIRED III
APPIRED III study is getting well on its way with 6 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt, UniMed Wien Vienna, Almazov Heart…
APPIRED III study is getting well on its way with 6 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt, UniMed Wien Vienna, Almazov Heart…
Computational model clarifies immune response during cardiac surgery 11 October 2018 A research team led by Peter Sloot, professor of Complex Adaptive Systems at the UvA, has managed to pinpoint…
Approval has been obtained in October 2018 to start with a solid organ transplantation study with RESCAP platform technology under supervision of PI Dr Joost van der Heijden from Vumc…
AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. First of these are a study in RA patients, based on excellent results with hRESCAP…
Following the start of patient inclusion in Europe, the first Asian center participating international study APPIRED lll has started patient recruitment. The National University Heart Centre, Singapore (NUHCS) is the…
Wageningen, 16 November 2017- Alloksys Life Sciences announced today that its international APPIRED lll clinical study has started with inclusion of the first patient in Eindhoven, the Netherlands. Patients undergoing…
Wageningen, 23 October 2017- Alloksys Life Sciences announced today that Kevin Driscoll has been appointed to its Supervisory Board. Dr. Driscoll is a proven Healthcare executive with 30 years experience…